Haemolytic transfusion reactions can be defined as the occurrence after transfusion of measurably increased destruction of red cells, of donor or recipient, by alloantibodies. They may be acute (occurring within 24 hours of transfusion) or delayed (when signs of red cell destruction do not occur until 4 to 10 days after transfusion). The severest signs and symptoms of acute reactions follow intravascular red cell lysis and progress to anaemia, fever, haemoglobinuria and jaundice. The subjective responses of pain, restlessness, nausea, skin flushing, dyspnoea and shock are mediated by cleavage products of complement (C3a, C5a) activated by red cell antigen-antibody reaction. The bleeding and renal failure complications that follow are multi-factoral in aetiology but also stem from the activation of intravascular clotting and from the vasomotor disturbances following histamine and kinin release.
INTRODUCTION
A haemolytic transfusion reaction may be defined as the occurrence after transfusion, of a measurable increase in the rate of destruction of red cells, either donor or recipient, by alloantibodies. For this review the reactions have been classified as acute if signs or symptoms develop at the time of infusion or within the subsequent 24 hours. Delayed haemolytic transfusion reactions, occurring 4 to 10 days after transfusion and presenting a special clinical syndrome of anaemia, jaundice, often fever and only rarely haemoglobinuria and oliguria, will also be discussed. Although clinical features will be stressed, often an astute laboratory worker finding spherocytosis or a positive direct antiglobulin test in posttransfusion blood is responsible for the initial step in delineating the occurrence of a haemolytic transfusion reaction. the least common type of transfusion reaction (accounting for 0.7070 of reported reactions in 1974 in Edinburgh hospitals). However, despite the increasing expertise in red cell serology, transfusion reactions due to red cell incompatibility do still occur. Most cases are documented only anecdotally amongst colleagues. A few appear as newspaper or medical defence union reports when medicolegal consequences ensue. Table 1 summarises the results of several larger surveys and includes the local experience of the Sydney hospitals whose staff participate in a monthly antibody review meeting. Only one acute haemolytic reaction due to Anti-AI following plasma infusion was reported in the review period. A minimum of 6 cases of delayed transfusion reaction were reported amongst an estimated total of 28,000 units transfused. Table 2 lists the signs and symptoms that a patient experiencing acute intravascular haemolysis may develop. As highlighted by an asterisk in that table, an anaesthetised [1977] [1978] [1979] or unconscious patient may show hypotension as the only immediate manifestation before subsequently developing serious complications of bleeding and renal failure. The classic descriptions of the immediate symptoms are identical with those described centuries ago with transfusions of animal blood. 2 The same text details these symptoms in patients inadvertently given ABO incompatible blood or experimental subjects given small injections of washed incompatible red cells. Acute haemolytic reactions -signs and symptoms (a) Immediate I.
I. ACUTE HAEMOLYTIC REACTIONS (a) Signs and symptoms
Pain -lumbar, sternal or IV.
2.
Fever ± chills and rigors.
3.
Restlessness, Nausea (vomiting).
4.
Skin Flushing (urticaria/dyspnoea). 5.
'Hypotension.
(b) Subsequent 6. 'Intractable Bleeding (operation or IV site). 7.
'Haemoglobinuria. 8.
'Oliguria (or anuria). 9.
'Jaundice and Anaemia.
'Present in anaesthetised or unconscious patient.
(b) Pathogenesis of acute symptoms
The common factor in the production of the acute symptoms of intravascular haemolysis and the subsequent development of bleeding is the activation of complement in the recipient following antigen-antibody binding. IgM alloantibodies (such as Anti-A and Anti-B) bind complement more efficiently than alloantibodies of IgG type. During complement activation, low molecular weight fragments are cleaved from both C3 and C5. C3a is a basic peptide of molecular weight 8,900, C5a is larger (mol. wt. = 17,000); both, in nanomolar amounts, release histamine from mast cells. The released histamine in turn enhances capillary permeability and produces oedema and contraction of smooth muscle. The vasomotor changes that ensue may be aggravated by "kinin-like" activity of C2 fragments and additionally by nonhistamine-dependent kinin activity of C3a. ( 
c) Pathogenesis of bleeding complications
The development of a disseminated intravascular coagulation (DIC) syndrome with fall in platelets, fibrinogen and Factors 11, V and VIII after intravascular haemolysis was attributed to release of thromboplastic substances from erythrocyte stroma (e.g. erythrocytin -a phospholipid procoagulant). Animal experiments have demonstrated more marked coagulation abnormalities with incompatible lysed red cells than with autologous lysed cells. The triggering of the DIC state that may lead to intractable bleeding may be the antigen-antibody reaction itself activating Hageman factor, platelets and leucocytes. The whole process of intravascular coagulation may be Anaesthesia and Intensive Care. Vol. VIII, No. 2, May, 1980 enhanced by reticuloendothelial blockade. 3 (d) Pathogenesis of acute renal failure Following a haemolytic transfusion reaction an acute transient functional renal shutdown may occur. More seriously, and usually after large volumes of incompatible blood have been transfused, acute tubular necrosis or renal cortical necrosis can occur. Although unproven in bumans, haemoglobin is not directly toxic to the renal tubule in experimental animals. Schmidt and Holland 4 in 1967 induced renal failure in two subjects after infusion of incompatible red cell stroma only. The main factors responsible for the renal tubular ischaemia are probably -(i) the vasomotor changes induced through histamine release by complement activation cleavage products or from kinin release either by the same process or following activation of Hageman factor directly by the antigen-antibody complex.
(ii) following DIC the deposition of fibrin in the renal micro-circulation.
Both changes lead to decreased renal cortical per fusion and this may be aggravated by generalized hypotension that results either from the condition in the patient that necessitated the transfusion or from continued hypovolaemia and hypotension following the reaction. Goldfinger 5 discusses these various facets in detail and reviews the supporting experimental evidence. (e) Symptoms and pathogenesis of extravascular red cell destruction Fever, chills, rigors, jaundice and occasionally haemoglobulinuria have been described following incompatible transfusions that involve non-complement binding IgG alloantibodies, especially those with specificity in the Rhesus system. Red cells bearing bound IgG molecules are partially or completely phagocytosed by mononuclear cells, particularly the tissue macrophages of the spleen where there is less competitive blockage by plasma IgG. Haemoglobinaemia ensues when the haptoglobin binding of the plasma is exceeded. The fever observed in the experiments of landl and Kaplan 6 was attributed to the splenic sequestration. (Table 3) The alloantibody causing an acute haemolytic transfusion reaction may be present in the recipient or be transfused with donor units or plasma (products) to react with either the recipient's cells or the cells of other donor units previously or subsequently transfused. The volume, titre, immunoglobulin class, complement binding potential and antigenic specificity of the antibody are of major importance. Severest reactions usually occur when large amounts of ABO-incompatible blood are infused, usually as the result of clerical errors in blood sample collection, in the crossmatch laboratory or at the time of blood administration. By contrast in the recent series of Pineda, Brzica and TaswelF from the Mayo Clinic only two of the 23 acute reactions were due to Anti-A (or Anti-B) alloantibodies: (one fatal case followed infusion of 0 blood with high Anti-A titre into an A recipient). Eight of the acute haemolytic reactions were due to lytic Anti-Kell antibodies undetected before transfusion in either the recipients or donor units. As all case reports illustrate, the host response to an acute haemolytic event is variable. The histamine and kinin-mediated acute symptoms may not occur and most certainly will be masked in a patient who is unconscious, anaesthetized or receiving narcotic sedation. Mollison 2 and Wallace 8 both stress how few of their personally observed cases of acute ABO-incompatible reactions have proceeded to bleeding or renal complications. However, as Goldfinger 5 points out, maintenance of circulatory integrity with colloid intravenous fluids after recogllltlOn of the transfusion reaction is of utmost importance in preventing acute renal failure.
(g) Differential diagnosis of acute haemolytic transfusion reactions
In all cases the occurrence of signs or symptoms listed in Table 2 occurring during or shortly after the infusion of blood or blood products should lead to cessation of the infusion for a clerical check and laboratory investigation to exclude a red cell antigen-alloantibody reaction. Many of the signs and symptoms may also occur in the situations listed in Table 4 and similar bleeding and renal failure complications may occur, particularly following the infusion of infected blood or plasma. Haemolytic anaemias (e.g. AIHA, Favism).
2.
Infections (malaria, clostridial septicaemia).
3.
Infusion of hypotonic solutions. Thermal damage (overheating, freezing).
2.
Administration of infected blood.
3.
Administration of aged red cells.
4.
Damage by extra-corporeal machines, or concomitantly administered drugs.
DELAYED HAEMOLYTIC TRANSFUSION REACTIONS (DHTR)
When incompatible red cells are transfused, the amount of antibody in a recipient's serum may be too low to be detected or to cause rapid red cell destruction. The transfusion may provoke an anamnestic immune response so that 4 to 10 days after transfusion there is a rapid increase in antibody concentration and rapid destruction of the transfused red cells. (Table 5) Delayed haemolytic transfusion reactions (I) AlIoantibody in recipient too low for -(a) Detection (b) Red cell destruction at time of transfusion. (2) Anamnestic immune response. (3) Jaundice, anaemia ± haemoglobinuria 4 to 10 days later.
Clinically, the patient becomes jaundiced 5 to 7 days after a transfusion and symptoms of anaemia may redevelop if many transfused red cells are eliminated. Haemoglobinuria has been reported in several case reports (associated with anti-Jk b , Anti-c and Anti-U alloantibodies). then a diuresis may be induced with intravenous frusemide 20-80 mg. (5) In severe reactions with coagulation disturbances replace coagulation factor and platelet deficiencies and consider heparinization. (6) If evidence of acute tubular necrosis develops commence standard therapy for acute renal failure. For patients recognized in the haemolytic phase of a delayed transfusion reaction, maintenance of diuresis and correction of any hypovolaemia is also important. Transfusion with compatible cells will correct the anaemia. CONCLUSION Despite the advances in red cell serology in the last three decades, haemolytic transfusion reactions are still being recognised in our hospitals. If they cannot be entirely prevented then the safety of the patient depends on early recognition and treatment of these complications. All who prescribe, crossmatch, set up or monitor the administration of blood should be aware of the pathogenesis, clinical manifestations and immediate management of haemolytic transfusion reactions.
